Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000672888 | SCV000798038 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-02-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001047995 | SCV001211984 | pathogenic | not provided | 2024-01-09 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1295*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (rs764797292, gnomAD 0.002%). This premature translational stop signal has been observed in individuals with Usher syndrome (PMID: 10909849, 22004887, 24160897). ClinVar contains an entry for this variant (Variation ID: 556829). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
SN ONGC Dept of Genetics and Molecular biology Vision Research Foundation | RCV003389479 | SCV003927075 | pathogenic | Usher syndrome | 2022-12-31 | criteria provided, single submitter | research | |
Genome- |
RCV003453359 | SCV004182300 | pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001271229 | SCV004182301 | pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003453359 | SCV004208297 | pathogenic | Retinitis pigmentosa 39 | 2023-11-14 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000672888 | SCV005638385 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-05-22 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001271229 | SCV001452237 | pathogenic | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |